CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

CRSP

Insider Sentiment (TTM):

Last Purchase:2025-08-06Last Sale:2026-05-29Shares Purchased (TTM):0Shares Sold (TTM):260,076

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:72,810,930Shares Outstanding:96,051,228Institutional Ownership Pct.:75.80%

Earnings Market Reaction:

Filing Date:2026-08-03Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	291	423	348	286	194	235	298	226	484	707	389	528
Marketable Securities Current	2,073	2,018	1,628	1,629	1,528	1,620	1,606	1,710	1,517	1,401	1,304	1,212
Accounts Receivable Net Current	-	-	0	0	0	0	25	0	0	0	200	-
Prepaid Expense And Other Assets Current	7	7	10	13	12	12	8	8	9	11	14	21
Assets Current	2,372	2,448	1,986	1,929	1,734	1,868	1,937	1,944	2,010	2,120	1,908	1,761
Property Plant And Equipment Net	108	112	116	121	125	129	134	139	143	147	152	156
Restricted Cash Noncurrent	8	8	8	8	8	8	12	12	12	12	12	12
Operating Lease Right Of Use Asset	126	129	132	135	138	140	143	146	149	151	154	156
Marketable Securities Noncurrent	-	0	0	28	-	-	0	0	11	0	2	0
Finite Lived Intangible Assets Net	-	-	-	-	-	-	0	0	0	0	0	0
Other Assets Noncurrent	38	29	24	24	25	21	16	16	15	9	2	2
Assets	2,651	2,726	2,265	2,245	2,030	2,166	2,242	2,256	2,340	2,439	2,230	2,087
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	11	14	11	12	10	13	15	16	9	16	38	26
Accrued Liabilities Current	70	75	89	84	74	85	41	47	92	76	45	66
Contract With Customer Liability Current	15	15	16	1	2	3	4	4	5	4	4	4
Taxes Payable Current	0	1	1	3	1	1	0	1	0	1	0	0
Operating Lease Liability Current	19	19	19	18	18	18	17	17	16	16	16	15
Other Liabilities Current	17	13	13	0	0	0	10	5	5	5	5	0
Liabilities Current	133	136	149	119	104	119	88	90	128	119	109	111
Contract With Customer Liability Noncurrent	-	-	0	12	12	12	12	12	13	14	14	16
Long Term Debt	586	585	-	-	-	-	-	-	-	-	-	-
Operating Lease Liability Noncurrent	179	184	188	193	197	202	206	211	215	219	223	227
Other Liabilities Noncurrent	6	6	6	5	4	3	3	4	4	4	1	5
Liabilities	904	911	343	329	319	337	310	316	359	355	347	359
Stockholders Equity
Common Stock Value	3	3	3	3	3	3	3	3	3	3	2	2
Treasury Stock Value	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Additional Paid In Capital Common Stock	3,910	3,884	3,862	3,725	3,415	3,324	3,294	3,255	3,224	3,199	2,878	2,821
Retained Earnings Accumulated Deficit	-2,162	-2,070	-1,948	-1,817	-1,710	-1,502	-1,366	-1,329	-1,243	-1,116	-1,000	-1,089
Accumulated Other Comprehensive Income Loss Net Of…	-5	-2	5	5	4	4	2	11	-3	-2	2	-7
Stockholders Equity	1,747	1,815	1,922	1,916	1,711	1,829	1,932	1,940	1,981	2,084	1,883	1,728
Liabilities And Stockholders Equity	2,651	2,726	2,265	2,245	2,030	2,166	2,242	2,256	2,340	2,439	2,230	2,087
Common Stock Par Or Stated Value Per Share	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	71.5	0.03	0.03
Common Stock Shares Authorized	144	132	132	132	132	132	132	132	132	130	127	-
Common Stock Shares Issued	97	97	96	94	89	87	86	86	85	85	80	80
Shares Outstanding	97	96	96	94	88	86	86	85	85	85	80	79
Treasury Stock Common Shares	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	4.85%	2.50%	-13.14%	-	-	-	-	-	-	-	-	-
2025	9.44%	43.21%	95.30%	-13.02%	3.49%	13.46%	4.21%	-1.48%	-8.46%	15.47%	1.19%	5.52%
2024	0.84%	1.35%	8.69%	-3.91%	-4.71%	-4.63%	1.61%	-20.53%	-13.78%	14.92%	-17.59%	-3.46%
2023	-	-	-	4.53%	-6.10%	-19.86%	33.09%	21.36%	18.28%	-11.48%	-26.38%	-37.91%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	17.85	17.96	13.32	16.22	16.61	15.64	22.07	21.64	15.73	17.81	17.54	15.83
Quick Ratio	17.79	17.92	13.25	16.10	16.49	15.53	21.97	21.55	15.66	17.72	17.41	15.64
Working Capital	2.24B	2.31B	1.84B	1.81B	1.63B	1.75B	1.85B	1.85B	1.88B	2.00B	1.80B	1.65B
Leverage & Debt
Debt to Equity	0.52	0.50	0.18	0.17	0.19	0.18	0.16	0.16	0.18	0.17	0.18	0.21
Debt Ratio	0.34	0.33	0.15	0.15	0.16	0.16	0.14	0.14	0.15	0.15	0.16	0.17
Efficiency & Turnover
Asset Turnover TTM	0.01	0.00	0.00	0.02	0.02	0.02	0.02	0.09	0.09	0.12	0.17	0.08
Days Sales Outstanding TTM	-	-	-	-	-	-	1,100.46	-	-	-	196.66	-
Receivables Turnover TTM	-	-	-	-	-	-	0.33	-	-	-	1.86	-
Per Share Metrics
Diluted EPS TTM	-4.67	-5.92	-6.47	-5.35	-5.37	-4.49	-4.34	-2.81	-3.13	-2.65	-1.94	-4.45
Free Cash Flow Per Share TTM	-3.85	-4.18	-3.85	-3.32	-3.74	-3.58	-1.71	-2.24	-1.48	-2.04	-3.41	-3.68
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-3,989.99%	-15,754.20%	-18,933.65%	-1,498.28%	-1,451.95%	-1,259.20%	-1,250.38%	-163.88%	-175.38%	-109.91%	-59.95%	-249.20%
Net Profit Margin TTM	-3,368.72%	-13,856.54%	-16,569.77%	-1,273.70%	-1,229.43%	-1,023.64%	-981.54%	-118.13%	-131.44%	-79.91%	-41.38%	-207.95%
Growth Metrics
Net Revenue Growth (1Y)	-64.80%	-89.11%	-90.59%	-81.10%	-81.18%	-86.13%	-89.95%	19.31%	18.89%	171.01%	30,885.48%	1,106.49%
Net Income Growth (1Y)	-3.56%	47.42%	58.80%	103.80%	75.99%	77.61%	138.43%	-32.23%	-36.09%	-58.56%	-76.37%	-48.07%
EPS Growth (1Y)	-13.00%	31.90%	48.97%	90.25%	71.65%	69.05%	123.91%	-36.86%	-40.48%	-60.14%	-76.81%	-48.99%
Valuation Metrics
P/E TTM	-11.67	-8.04	-8.11	-12.12	-9.05	-7.58	-9.07	-16.71	-17.26	-25.68	-32.28	-10.20
P/B TTM	3.01	2.52	2.45	3.09	2.48	1.60	1.72	2.06	2.32	2.68	2.63	2.09
P/S TTM	393.06	1,113.61	1,343.50	154.35	111.30	77.62	88.98	19.74	22.68	20.52	13.36	21.20
Market Cap	5.26B	4.57B	4.72B	5.92B	4.24B	2.92B	3.32B	4.00B	4.59B	5.58B	4.96B	3.60B
Enterprise Value	5.56B	4.73B	4.37B	5.63B	4.04B	2.69B	3.02B	3.78B	4.10B	4.87B	4.57B	3.08B
Calculated Values
Free Cash Flow TTM	-371.33M	-401.18M	-345.93M	-303.14M	-325.57M	-307.86M	-144.68M	-191.20M	-126.04M	-166.55M	-269.85M	-292.55M
Net Debt	294.86M	162.16M	-347.56M	-286.50M	-193.62M	-235.18M	-298.26M	-225.67M	-484.47M	-707.43M	-389.48M	-527.77M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-29Sale

Owner: Patel, Naimish

Title: Chief Medical Officer

Shares: 3,786

Price/Share: $55.62

Value: $210,577.32

Shares Owned: 19,357

Relationship: Officer

Ownership: Direct

2026-03-23Sale

Owner: Kulkarni, Samarth

Title: Chief Executive Officer

Shares: 10,020

Price/Share: $46.78

Value: $468,735.60

Shares Owned: 255,501

Relationship: Director,Officer

Ownership: Direct

2026-03-23Sale

Owner: Prasad, Raju

Title: Chief Financial Officer

Shares: 3,708

Price/Share: $46.78

Value: $173,460.24

Shares Owned: 15,565

Relationship: Officer

Ownership: Direct

2026-03-23Sale

Owner: Kasinger, James R.

Title: General Counsel and Secretary

Shares: 3,182

Price/Share: $46.78

Value: $148,853.96

Shares Owned: 94,308

Relationship: Officer

Ownership: Direct

2026-03-16Sale

Owner: Patel, Naimish

Title: Chief Medical Officer

Shares: 3,150

Price/Share: $48.26

Value: $152,019.00

Shares Owned: 13,143

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-29	Patel, Naimish	Officer	Chief Medical Officer	Direct	Sale	3,786	55.62	$210,577.32	19,357	4
2026-03-23	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	10,020	46.78	$468,735.60	255,501	4
2026-03-23	Prasad, Raju	Officer	Chief Financial Officer	Direct	Sale	3,708	46.78	$173,460.24	15,565	4
2026-03-23	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	3,182	46.78	$148,853.96	94,308	4
2026-03-16	Patel, Naimish	Officer	Chief Medical Officer	Direct	Sale	3,150	48.26	$152,019.00	13,143	4
2026-03-16	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	3,450	48.26	$166,497.00	91,240	4
2026-03-16	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	10,349	48.26	$499,442.74	245,834	4
2026-03-16	Prasad, Raju	Officer	Chief Financial Officer	Direct	Sale	9,869	48.26	$476,277.94	13,773	4
2026-03-11	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	2,800	52.80	$147,840.00	87,815	4
2026-03-11	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	9,798	52.80	$517,334.40	235,558	4
2026-02-19	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	2,112	52.58	$111,048.96	85,115	4
2026-02-19	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	6,967	52.58	$366,324.86	226,106	4
2026-01-22	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	60,000	60.23	$3,613,800.00	134,201	4
2026-01-22	Prasad, Raju	Officer	Chief Financial Officer	Direct	Sale	34,972	60.19	$2,104,964.68	6,767	4
2026-01-06	Prasad, Raju	Officer	Chief Financial Officer	Direct	Sale	29,700	60.13	$1,785,861.00	6,767	4
2025-12-22	Prasad, Raju	Officer	Chief Financial Officer	Direct	Sale	10,000	56.11	$561,100.00	6,767	4
2025-10-17	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	50,895	67.91	$3,456,279.45	254,201	4
2025-10-14	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	1,076	66.60	$71,661.60	83,402	4
2025-10-14	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	4,242	66.60	$282,517.20	205,096	4
2025-08-18	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	13,081	58.15	$760,660.15	207,004	4
2025-08-06	Treco, Douglas A	Director	-	Direct	Purchase	20,000	57.03	$1,140,600.00	22,000	4
2025-07-16	George, Simeon	Director	-	Indirect	Purchase	989,812	52.03	$51,499,918.36	1,730,179	4
2025-05-29	Patel, Naimish	Officer	Chief Medical Officer	Direct	Sale	3,932	35.94	$141,316.08	6,068	4
2025-04-03	Patel, Naimish	Officer	Chief Medical Officer	Direct	Purchase	1,508	32.96	$49,703.68	1,508	4
2025-03-21	Prasad, Raju	Officer	Chief Financial Officer	Direct	Sale	2,197	41.23	$90,582.31	16,767	4
2025-03-21	Bruno, Julianne	Officer	Chief Operating Officer	Direct	Sale	1,714	41.23	$70,668.22	10,544	4
2025-03-21	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	3,185	41.23	$131,317.55	81,729	4
2025-03-21	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	10,031	41.23	$413,578.13	195,085	4
2025-03-17	Prasad, Raju	Officer	Chief Financial Officer	Direct	Sale	3,762	41.80	$157,251.60	12,714	4
2025-03-12	Bruno, Julianne	Officer	Chief Operating Officer	Direct	Sale	190	43.32	$8,230.80	8,508	4
2025-03-12	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	1,116	43.32	$48,345.12	78,664	4
2025-03-12	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	4,462	43.32	$193,293.84	185,428	4
2025-02-26	Greene, John	Director	-	Direct	Purchase	7,000	44.85	$313,950.00	7,000	4
2025-02-19	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	18,360	55.21	$1,013,655.60	171,613	4
2025-02-19	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	1,947	52.80	$102,801.60	74,880	4
2025-02-19	Bruno, Julianne	Officer	Chief Operating Officer	Direct	Sale	333	52.80	$17,582.40	7,062	4
2025-02-18	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	11,640	55.05	$640,782.00	196,901	4
2024-12-02	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	15,000	55.10	$826,500.00	181,540	4
2024-11-11	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	30,000	55.85	$1,675,500.00	196,540	4
2024-10-14	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	1,089	46.28	$50,398.92	62,597	4
2024-10-14	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	4,293	46.28	$198,680.04	226,540	4
2024-06-21	Bruno, Julianne	Officer	Chief Operating Officer	Direct	Sale	3,366	56.09	$188,798.94	6,745	4
2024-04-15	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	19,582	60.14	$1,177,661.48	208,122	4
2024-03-15	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	72.52	$1,450,400.00	208,122	4
2024-03-15	Prasad, Raju	Officer	Chief Financial Officer	Direct	Sale	3,524	72.69	$256,159.56	6,476	4
2024-03-12	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	1,146	74.44	$85,308.24	61,174	4
2024-03-12	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	4,583	74.44	$341,158.52	208,122	4
2024-02-20	Kasinger, James R.	Officer	General Counsel and Secretary	Direct	Sale	1,913	79.67	$152,408.71	57,371	4
2024-02-20	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	6,370	79.67	$507,497.90	194,257	4
2024-02-15	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	80.88	$1,617,600.00	187,377	4
2024-01-29	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	50,000	60.80	$3,040,000.00	187,377	4
2024-01-16	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	20,000	62.50	$1,250,000.00	187,377	4
2023-05-30	Kulkarni, Samarth	Director,Officer	Chief Executive Officer	Direct	Sale	25,000	65.13	$1,628,250.00	387,377	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

75.80%

Inst. Shares: 72,810,930

Shares Outstanding: 96,051,228

2025-12-31

80.90%

Inst. Shares: 72,750,833

Shares Outstanding: 89,925,109

2025-09-30

74.68%

Inst. Shares: 68,183,743

Shares Outstanding: 91,305,337

2025-06-30

77.56%

Inst. Shares: 67,530,416

Shares Outstanding: 87,069,690

2025-03-31

68.05%

Inst. Shares: 58,479,740

Shares Outstanding: 85,938,720

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	72,810,930	96,051,228	75.80%
2025-12-31	72,750,833	89,925,109	80.90%
2025-09-30	68,183,743	91,305,337	74.68%
2025-06-30	67,530,416	87,069,690	77.56%
2025-03-31	58,479,740	85,938,720	68.05%
2024-12-31	58,835,268	84,359,126	69.74%
2024-09-30	54,070,759	85,234,926	63.44%
2024-06-30	53,785,767	84,920,929	63.34%
2024-03-31	52,234,162	81,794,630	63.86%
2023-12-31	48,318,815	79,220,930	60.99%
2023-09-30	46,826,404	79,414,098	58.96%
2023-06-30	46,621,397	79,091,061	58.95%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

CRISPR Therapeutics AG (CRSP) — SEC Financial Statements & Analysis

CRISPR Therapeutics AG (CRSP) is a biological products, (no diagnostic substances) company, incorporated in V8. CRISPR Therapeutics AG trades on Nasdaq as: CRSP. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), CRISPR Therapeutics AG reported a -64.80% year-over-year revenue growth, a Debt-to-Equity ratio of 0.52x, a Price-to-Sales (P/S) ratio of 393.06x (TTM), a Price-to-Book (P/B) ratio of 3.01x (TTM), at a market cap of $5.26B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -64.80%
Debt To Equity: 0.52x
P/S TTM: 393.06x
P/B TTM: 3.01x
Market Cap: $5.26B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is CRISPR Therapeutics AG in?

CRISPR Therapeutics AG (CRSP) operates in the Biological Products, (No Diagnostic Substances) industry.

What is CRSP's market cap?

CRISPR Therapeutics AG (CRSP) has a market capitalization of $5.26B as of 2026-06-30.

What exchange does CRSP trade on?

CRISPR Therapeutics AG (CRSP) trades on the Nasdaq.

Where is CRISPR Therapeutics AG incorporated?

CRISPR Therapeutics AG is incorporated in Switzerland.